Literature DB >> 30310458

Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?

Antoni Martínez-Rubio1,2, Gheorghe-Andrei Dan1,2.   

Abstract

Entities:  

Year:  2016        PMID： 30310458      PMCID： PMC6159536          DOI： 10.15420/ecr.2016.11.2.ED2

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN： 1758-3756


× No keyword cloud information.
  18 in total

Review 1.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

Review 2.  Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?

Authors:  Endalkachew A Alamneh; Leanne Chalmers; Luke R Bereznicki
Journal:  Am J Cardiovasc Drugs       Date:  2016-06       Impact factor: 3.571

3.  Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  Stroke       Date:  2010-10-21       Impact factor: 7.914

4.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

5.  Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Authors:  David J Graham; Marsha E Reichman; Michael Wernecke; Rongmei Zhang; Mary Ross Southworth; Mark Levenson; Ting-Chang Sheu; Katrina Mott; Margie R Goulding; Monika Houstoun; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal:  Circulation       Date:  2014-10-30       Impact factor: 29.690

6.  Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.

Authors:  Megan E Barra; John Fanikos; Jean M Connors; Katelyn W Sylvester; Gregory Piazza; Samuel Z Goldhaber
Journal:  Am J Med       Date:  2016-06-21       Impact factor: 4.965

7.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245

8.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

9.  Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.

Authors:  Sally Tamayo; W Frank Peacock; Manesh Patel; Nicholas Sicignano; Kathleen P Hopf; Larry E Fields; Troy Sarich; Shujian Wu; Daniel Yannicelli; Zhong Yuan
Journal:  Clin Cardiol       Date:  2015-01-14       Impact factor: 2.882

10.  Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Authors:  Torben Bjerregaard Larsen; Flemming Skjøth; Peter Brønnum Nielsen; Jette Nordstrøm Kjældgaard; Gregory Y H Lip
Journal:  BMJ       Date:  2016-06-16
View more
  1 in total

1.  Impact of an Integral Assistance on the Management of Patients with Chronic Heart Diseases.

Authors:  Román Freixa-Pamias; Pere Blanch Gràcia; Lluïsa Rodriguez Latre; Antoni Oliva Vicedo; Carmen Alonso Permanyer; Pilar Sánchez Chamero; Elisabet Mena Sebastià; Miriam García Bermúdez; Alberto Cabestrero de Diego; Angels González Guardia; Elena Salas González; Carolina Bosch Carabante; José Manuel Depares López; Mireia Sans Corrales; Juan Francisco Pajares Díaz-Meco; Jordi Vericat Garcia; Maria Jesús Megido Badía; Jordi Vilarasau Farre; Maria Rotllan Terradellas; Angel Jover Blanca
Journal:  Eur Cardiol       Date:  2017-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.